NASDAQ:AKBA • US00972D1054
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AKEBIA THERAPEUTICS INC (AKBA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | BTIG | Maintains | Buy -> Buy |
| 2026-02-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-02 | BTIG | Reiterate | Buy -> Buy |
| 2025-12-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-29 | BTIG | Maintains | Buy -> Buy |
| 2025-04-28 | Leerink Partners | Initiate | Outperform |
| 2025-04-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-01 | Jefferies | Initiate | Buy |
| 2025-03-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-28 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 194.623M -33.46% | 160.18M -17.70% | 236.196M 47.46% | 240.54M 1.84% | 217.57M -9.55% | 257.41M 18.31% | 318.97M 23.92% | 432.53M 35.60% | 494.1M 14.23% | 546M 10.50% | 594.68M 8.92% | |
| EBITDA YoY % growth | -6.848M -329.03% | -8.71M -27.19% | 27.268M 413.07% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -44.475M -28.17% | -46.214M -3.91% | 25.999M 156.26% | 48.627M 87.03% | 15.384M -68.36% | 113.83M 639.92% | 127.44M 11.96% | 222.31M 74.44% | 274.09M 23.29% | 321.83M 17.42% | 362.62M 12.67% | |
| Operating Margin | -22.85% | -28.85% | 11.01% | 20.22% | 7.07% | 44.22% | 39.95% | 51.40% | 55.47% | 58.94% | 60.98% | |
| EPS YoY % growth | -0.28 36.36% | -0.33 -17.86% | -0.02 93.94% | -0.08 -295.25% | -0.08 -6.45% | 0.12 237.37% | 0.07 -38.23% | 0.18 157.14% | 0.36 94.44% | 0.55 54.29% | 0.72 31.48% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 -174.80% | -0.02 | 0.01 | 0.05 195.21% |
| Revenue Q2Q % growth | 54.219M -5.44% | 56.676M -9.28% | 76.665M 30.46% | 91.659M 59.07% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 1.103M -91.72% | 1.909M -86.35% | 10.538M 166.85% | 20.121M 468.99% |
All data in USD
11 analysts have analysed AKBA and the average price target is 4.69 USD. This implies a price increase of 269.45% is expected in the next year compared to the current price of 1.27.
AKEBIA THERAPEUTICS INC (AKBA) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of AKEBIA THERAPEUTICS INC (AKBA) is -0.02 USD and the consensus revenue estimate is 54.22M USD.
The consensus rating for AKEBIA THERAPEUTICS INC (AKBA) is 87.2727 / 100 . This indicates that analysts generally have a positive outlook on the stock.